- Home
- XGN vs RFL Comparison
XGN vs RFL Comparison
Compare XGN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- RFL
- Stock Information
- Founded
- XGN 2002
- RFL 2017
- Country
- XGN United States
- RFL United States
- Employees
- XGN N/A
- RFL N/A
- Industry
- XGN Medical Specialities
- RFL Real Estate
- Sector
- XGN Health Care
- RFL Finance
- Exchange
- XGN Nasdaq
- RFL Nasdaq
- Market Cap
- XGN 49.4M
- RFL 48.4M
- IPO Year
- XGN 2019
- RFL N/A
- Fundamental
- Price
- XGN $2.73
- RFL $2.29
- Analyst Decision
- XGN Buy
- RFL
- Analyst Count
- XGN 1
- RFL 0
- Target Price
- XGN $7.00
- RFL N/A
- AVG Volume (30 Days)
- XGN 25.4K
- RFL 57.4K
- Earning Date
- XGN 11-11-2024
- RFL 10-28-2024
- Dividend Yield
- XGN N/A
- RFL N/A
- EPS Growth
- XGN N/A
- RFL N/A
- EPS
- XGN N/A
- RFL N/A
- Revenue
- XGN $56,660,000.00
- RFL $540,000.00
- Revenue This Year
- XGN $9.98
- RFL N/A
- Revenue Next Year
- XGN $13.63
- RFL N/A
- P/E Ratio
- XGN N/A
- RFL N/A
- Revenue Growth
- XGN 7.05
- RFL 92.86
- 52 Week Low
- XGN $1.30
- RFL $1.29
- 52 Week High
- XGN $3.71
- RFL $2.29
- Technical
- Relative Strength Index (RSI)
- XGN 42.55
- RFL 84.99
- Support Level
- XGN $2.64
- RFL $2.00
- Resistance Level
- XGN $3.03
- RFL $1.94
- Average True Range (ATR)
- XGN 0.16
- RFL 0.10
- MACD
- XGN -0.04
- RFL 0.03
- Stochastic Oscillator
- XGN 16.51
- RFL 80.74
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.